Authors

Latest:

Dr. Gafita on Prognostic Models for Treatment With 177Lu-PSMA-617 in mCRPC

Andrei Gafita, MD, discusses key takeaways from a retrospective analysis evaluating lutetium-177 PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Steven J. Cohen, MD

Latest:

Dr. Cohen on the Importance of Obtaining an Adequate Tissue Sample in GI Malignancies

Steven J. Cohen, MD, discusses the importance of obtaining an adequate tissue sample for molecular testing in gastrointestinal cancers.

Anne Chiang, MD, PhD, Yale Cancer Center

Latest:

Dr Chiang on Managing Advanced NSCLC Without Driver Mutations

Anne Chiang, MD, PhD, discusses treating patients with advanced non–small cell lung cancer without driver mutations.

Ryan D. Cassaday, MD, University of Washington/Fred Hutch

Latest:

Emerging Data Supporting the use of Tisagenlecleucel in Patients with R/R Acute Lymphoblastic Leukemia

Led by Dr Armin Ghobadi, the panel reviews data from a study regarding CD19 CAR T-cell therapy use in adults with B-Cell ALL.

Brandon Blue, MD

Latest:

Dr. Blue on the Importance of Early Intervention in Relapsed/Refractory Multiple Myeloma

Brandon Blue, MD, discusses the importance of early intervention in relapsed/refractory multiple myeloma.

Ernest S. Han, MD, PhD

Latest:

Dr Han on the Use of HIPEC in Ovarian Cancer

Ernest S. Han, MD, PhD, discusses the use of hyperthermic intraperitoneal chemotherapy in ovarian cancer.

Praveen Ramakrishnan, MD, MS

Latest:

Dr. Ramakrishnan on the Evolving Landscape of CAR T-cell Therapy in DLBCL

Praveen Ramakrishnan, MD, MS, discusses the evolving landscape of CAR T-cell therapy in diffuse large B-cell lymphoma.

Stephen Freedland, MD, Cedars-Sinai Medical Center

Latest:

Advanced Prostate Cancer: Remaining Challenges

Experts discuss challenges and unmet needs in men with advanced prostate cancer who are undergoing treatment with androgen deprivation therapy.

Wenxin Xu, MD

Latest:

Dr Xu on Changes in Systemic Therapy in RCC

Wenxin (Vincent) Xu, MD, on evolving systemic therapy and the utilization of biomarkers in the treatment of renal cell carcinoma.

Bradley J. Monk, MD, FACS, FACOG

Latest:

Treatment Strategies in Non-Responders to Chemotherapy

Bradley J. Monk, MD, FACS, FACOG, and Christian Marth, MD, PhD, share treatment approaches to patients with endometrial cancer with a low response rate to chemotherapy, highlighting a biomarker-based approach.

Benjamin Creelan, MD

Navid Redjal, MD, FAANS

Latest:

Dr. Redjal on Technological Advances in Neurosurgical Oncology

Navid Redjal, MD, FAANS, discusses technological advances that have impacted neurosurgical oncology.

Steven Vernino, MD, PhD

Latest:

Clinical Pearls and the Future of LEMS

Experts provide clinical pearls on treating Lambert-Eaton myasthenic syndrome and small cell lung cancer and share upcoming advances and trials they look forward to.

Mansi Dalal, MD

Latest:

Dr. Dalal on Graft Failure in Pediatric Non-malignant Disorders

Mansi Dalal, MD, discusses findings from a study investigating graft failure risk factors in pediatric patients receiving allogeneic hematopoietic stem cell transplant for non-malignant disorders.

Turab J Mohammed, MD

Latest:

Dr Mohammed on the Challenges of Diagnosing BPDCN

Turab J. Mohammed, MD, discusses challenges associated with the diagnosis of blastic plasmacytoid dendritic cell neoplasm, and strategies to improve early diagnosis of this disease.

Ashkan Emadi, MD, PhD

Latest:

Dr Emadi on Initial Responses With Venetoclax Plus PegC in R/R AML

Ashkan Emadi, MD, PhD, discusses responses achieved with venetoclax plus PegC in patients with venetoclax-pretreated, relapsed/refractory AML.

Volkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf

Latest:

Addressing Treatment Gaps in HER2+ MBC

Unmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.

Theresa Boyle, MD, PhD

Latest:

Dr. Boyle on Approaching Biomarker Testing in Lung Cancer

Theresa Boyle, MD, PhD, discusses the current approach to biomarker testing in lung cancer.

Ahmed Elkhanany, MD

Latest:

Dr Elkhanany on Biological Drivers of Progression in ER+ Metastatic Breast Cancer

Ahmed Elkhanany, MD, discusses biological drivers of disease in patients with estrogen receptor–positive breast cancer who have disease progression shortly after initiating first-line therapy, as well as the importance of performing comprehensive genetic testing in these patients to determine subsequent treatment approaches.

Paul Szabolcs, MD

Latest:

Rapid Readout: HSCT With Omidubicel Achieved Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to UCB Transplantation

Expert hematologist/oncologist Paul Szabolcs, MD, reviews positive data from a clinical trial comparing hematopoietic stem cell transplantation and omidubicel with standard cord blood transplantation.